

# Leo J Y Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3252962/publications.pdf>

Version: 2024-02-01

22  
papers

2,436  
citations

361413

20  
h-index

677142

22  
g-index

22  
all docs

22  
docs citations

22  
times ranked

4475  
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcription Elongation Machinery Is a Druggable Dependency and Potentiates Immunotherapy in Glioblastoma Stem Cells. <i>Cancer Discovery</i> , 2022, 12, 502-521.	9.4	29
2	The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. <i>Cancer Discovery</i> , 2021, 11, 480-499.	9.4	218
3	CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. <i>Cancer Discovery</i> , 2021, 11, 1192-1211.	9.4	78
4	Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	37
5	Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	9
6	Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cell-Mediated Tumor Killing. <i>Cancer Discovery</i> , 2020, 10, 382-393.	9.4	31
7	Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. <i>Cell</i> , 2020, 181, 1329-1345.e24.	28.9	79
8	Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	112
9	Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock. <i>Cancer Discovery</i> , 2019, 9, 1556-1573.	9.4	172
10	SUFU: The Jekyll and Hyde of the Cerebellum. <i>Developmental Cell</i> , 2019, 48, 131-132.	7.0	1
11	Glioma Stem Cell-Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling. <i>Cancer Discovery</i> , 2019, 9, 1248-1267.	9.4	120
12	Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. <i>Journal of Experimental Medicine</i> , 2019, 216, 1071-1090.	8.5	89
13	Reciprocal Signaling between Glioblastoma Stem Cells and Differentiated Tumor Cells Promotes Malignant Progression. <i>Cell Stem Cell</i> , 2018, 22, 514-528.e5.	11.1	185
14	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. <i>Nature</i> , 2018, 553, 101-105.	27.8	170
15	Inhibition of ID1-BMPR2 Intrinsic Signaling Sensitizes Glioma Stem Cells to Differentiation Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 383-394.	7.0	26
16	N-methyladenine DNA Modification in Glioblastoma. <i>Cell</i> , 2018, 175, 1228-1243.e20.	28.9	236
17	Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	112
18	Purine synthesis promotes maintenance of brain tumor initiating cells in glioma. <i>Nature Neuroscience</i> , 2017, 20, 661-673.	14.8	153

#	ARTICLE	IF	CITATIONS
19	Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. <i>Nature Medicine</i> , 2017, 23, 1352-1361.	30.7	279
20	MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells. <i>Cancer Research</i> , 2017, 77, 4947-4960.	0.9	91
21	Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. <i>Nature</i> , 2017, 547, 355-359.	27.8	156
22	CDC20 maintains tumor initiating cells. <i>Oncotarget</i> , 2015, 6, 13241-13254.	1.8	53